FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

The U.S. health regulator will not meet its Dec. 16 deadline to decide on the expanded use of Bristol Myers Squibb (BMY.N) and partner 2seventy bio's (TSVT.O) blood cancer therapy in earlier lines of treatment as it plans to seek the advice of experts, the companies said on Monday.